Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has decided to acquire 33,016,411 shares of PolyPeptide Group AG, a Swiss peptide CDMO specialist, for approximately KRW 2.71T through a tender offer to strengthen its business competitiveness.
📊 [Key Disclosure Details & Financial Summary]
- Target Company:
- Company Name & Nationality: PolyPeptide Group AG (Switzerland)
- Core Business: Peptide CDMO
- Total Shares Issued: 33,125,001 shares
- Capital Stock: KRW 612.7M (Applied conversion rate for CHF 331,250.01)
- Acquisition Details & Amount:
- Number of Shares to Acquire: 33,016,411 shares (Maximum acquirable shares excluding treasury shares)
- Acquisition Amount: KRW 2.71T / KRW 2,706,163,546,103 (CHF 44.31 per share, FX rate CHF/KRW 1,849.79 as of July 16, 2026)
- Post-Acquisition Ownership & Stake: 33,016,411 shares (100% stake)
- Financial Ratios: 24.47% of Total Assets (KRW 11.06T) and 36.32% of Total Equity (KRW 7.45T)
- Purpose & Schedule:
- Purpose: Strengthening business competitiveness by acquiring a peptide CDMO company
- Board Resolution Date: 2026-07-17 (4 outside directors attended, 0 absent)
- Scheduled Acquisition Date: 2026-11-30 (Payment within 10 business days following subscription close and merger clearances)
- Transaction Terms & Key Conditions:
- Payment Method: Cash payment (Public tender offer on the SIX Swiss Exchange)
- Funding Source: Internal cash reserves and debt financing
- Major Shareholder Commitment: Secured undertaking from Draupnir Holding B.V. (55.65% stake, 18,375,000 shares) to tender all its shares
- Minimum Acceptance Condition: Transaction is subject to validly and irrevocably tendered shares amounting to approximately 66.7% (2/3) or more of the target company’s fully diluted capital stock by the end of the tender offer period (offer lapses if condition is not met)
- External Evaluation: External appraisal by Anjin LLC concluded that the offer price of CHF 44.31 falls within the valuation range of CHF 31.43 to CHF 63.22 per share, with no grounds found to deem it inappropriate
- Target Company Financial Summary (As of FY2025):
- Total Assets: KRW 1.41T / KRW 1,410.2B
- Total Liabilities: KRW 828.7B
- Total Equity: KRW 581.5B
- Revenue: KRW 669.2B
- Net Income: KRW -36.1B (Continued net loss)
- Audit Opinion: Unqualified / Clean (BDO Ltd)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Satisfaction of Minimum Tender Conditions and Completion of Share Acquisition
This transaction is subject to meeting the minimum acceptance condition of validly tendered shares by the end of the offer period and obtaining regulatory merger clearances. Verifying whether the tender offer successfully closes and the share acquisition is actually completed is important for determining the final outcome of this transaction. Relevant updates can be verified in future amended disclosures and upcoming periodic reports.
📢 Disclaimer & Source Notice
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Disclaimer: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
